Solid Biosciences receives European orphan drug designation for SGT-003
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
April 28, 2026 8:01 AM EDT- Orphan drug designation from the European Commission underscores Solids commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy -Â
CHARLESTOWN, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the Company or Solid), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the European Commission (EC), acting upon the positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products, has granted Orphan drug designation to SGT-003 for the treatment of Duchenne muscular dystrophy... More
